A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/7105 (2006.01)
Patent
CA 2608120
The downregulation of PRP 19 (precursor RNA processing 19) protein expression results in effectively reducing the expression of SCD1 (stearyl CoA desaturase- 1), the key lipogenic enzyme, and its down-stream triacylglycerol synthesis enzymes, DGAT-1 (diacyglycerol acyltransferase-1) and GPAT (glycerol-phosphate acyltransferase), as well as the intracellular content of neutral lipids, the major target for treating obesity.
L'action de frénation de l'expression de la protéine PRP 19 (precursor RNA processing 19) permet de réduire efficacement l'expression de SCD1 (stearyl CoA desaturase-1), l'enzyme lipogénique clé, ainsi que les enzymes de synthèse triacylglycerol qui en découlent, DGAT-1 (diacyglycerol acyltransferase-1) et GPAT (glycerol-phosphate acyltransferase), ainsi que la teneur intracellulaire en lipides neutres, la cible majeur pour le traitement de l'obésité.
Chang Hui-Kyoung
Chang Ih-Seop
Cho Si-Young
Kim Dae-Gun
Lee Hyoung-Ho
Amorepacific Corporation
Smart & Biggar
LandOfFree
Pharmaceutical composition for the inhibition of lipogenesis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for the inhibition of lipogenesis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for the inhibition of lipogenesis... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1843297